Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CANbridge Pharmaceuticals, Inc.

News headline image
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy annual Meeting
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Consolidates Gene Therapy Portfolio
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the Treatment of Myasthenia Gravis
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Data on CAN106 to be Presented at Two Conferences
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Appoints Pauline Li as Senior Vice President of Clinical Development and Operations
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Appoints Dr. Lan Hu as New Independent Director
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Reports Positive Top-Line CAN106 Phase 1 Data
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Chinese Red Cross Foundation Rare Disease Mutual Assistance Fund Officially Launches
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Ltd Listed on Main Board of Hong Kong Stock Exchange
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Signs Collaboration Agreement with the Peking Union Medical College on Rare Disease Research
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals Enters into Exclusive Worldwide Research Collaboration and Licensing Agreement with Scriptr Global for Stitchr™ RNA Assembly Technology to Develop Gene Therapy Product Targeting Dystrophinopathies
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
News headline image
CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor
From CANbridge Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.